Experimental Human Pneumococcal Challenge With SPN3
- Status
- COMPLETED
- Phase
- NA
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
Exploring the Perspectives and Experiences of PrEP-eligible Black Women in Texas in Relation to Readiness for PrEP Uptake and Adherence
- Status
- COMPLETED
- Phase
- N/A
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)
- Status
- COMPLETED
- Phase
- PHASE3
TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension
- Status
- COMPLETED
- Phase
- PHASE3
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)
- Status
- COMPLETED
- Phase
- PHASE2
Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2